
|Articles|December 6, 2017
Dr. Pant on the Third-Line Setting for Metastatic CRC
Author(s)Shubham Pant, MD, MBBS
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).
Advertisement
Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).
According to Pant, there are not many options for patients with CRC in the third-line setting. Currently, regorafenib (Stivarga) and TAS-102 are the only options for this setting.
Next-generation sequencing is important to determine targets for treatment, explains Pant.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































